BMY Stock Recent News
BMY LATEST HEADLINES
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $2.07 per share a year ago.
Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most established and best-selling brands, blood thinner Eliquis and cancer treatments Opdivo and Revlimid.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Reports Second Quarter Financial Results for 2025.
Nine of the top sixteen Barron's Better Bets 'Safer' dividend dogs are attractively priced, offering dividends from $1K invested exceeding their share price. Analyst projections suggest 18-29% net gains for the top ten BBB Dogs by July 2026, with average risk 20% below the market. The dogcatcher strategy prioritizes stocks with high, reliable dividends and fair pricing, favoring underdogs poised for price corrections or dividend increases.
Bristol Myers Squibb (NYSE:BMY) is scheduled to release its earnings report on Thursday, July 31, 2025. For event-driven traders, examining historical stock performance around earnings announcements can provide valuable insights.
Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.
Often, great investing boils down to holding on to great stocks. It can be as simple as that.
Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing immunology drugs, backed by Bain's $300 million financing round, the companies said on Monday.
The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which will retain 20% equity in the new company.
PRINCETON, N.J. & BOSTON--(BUSINESS WIRE)--Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical.